Promising strategy for developing mRNA-based universal influenza virus vaccine for human population, poultry, and pigs– focus on the bigger picture

Rcheulishvili, Nino; Papukashvili, Dimitri; Liu, Cong; Ji, Yang; He, Yaohua; Wang, Peng George

doi:10.3389/fimmu.2022.1025884

Cited by 7 publications

(5 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Advantages include faster and cell-free manufacturing; the host cell produces the antigen after vaccination, with no risk of transportation into the nucleus and genomic integration, with the potential to develop "universal vaccines" effective against all strains. mRNA vaccines against avian influenza are currently undergoing research [79].…”

Section: Vaccinationmentioning

confidence: 99%

The Public Health Importance and Management of Infectious Poultry Diseases in Smallholder Systems in Africa

Grace,

Knight-Jones,

Melaku

et al. 2024

Foods

View full text Add to dashboard Cite

Poultry diseases pose major constraints on smallholder production in Africa, causing high flock mortality and economic hardship. Infectious diseases, especially viral diseases like Newcastle disease and highly pathogenic avian influenza (HPAI) and bacterial diseases, especially colibacillosis and salmonellosis, are responsible for most chicken losses, with downstream effects on human nutrition and health. Beyond production impacts, poultry diseases directly harm public health if zoonotic, can give rise to epidemics and pandemics, and facilitate antimicrobial resistance through treatment attempts. HPAI, campylobacteriosis, and salmonellosis are the priority zoonoses. Sustainable solutions for poultry health remain elusive despite recognition of the problem. This review summarises current knowledge on major poultry diseases in smallholder systems, their impacts, and options for prevention and control. We find biosecurity, vaccination, good husbandry, and disease-resistant breeds can reduce disease burden, but practical limitations exist in implementing these measures across smallholder systems. Treatment is often inefficient for viral diseases, and treatment for bacterial diseases risks antimicrobial resistance. Ethnoveterinary practices offer accessible alternatives but require more rigorous evaluation. Multisectoral collaboration and policies that reach smallholder poultry keepers are essential to alleviate disease constraints. Successful control will improve livelihoods, nutrition, and gender equity for millions of rural families. This review concludes that sustainable, scalable solutions for smallholder poultry disease control remain a critical unmet need in Africa.

show abstract

Section: Vaccinationmentioning

confidence: 99%

The Public Health Importance and Management of Infectious Poultry Diseases in Smallholder Systems in Africa

Grace,

Knight-Jones,

Melaku

et al. 2024

Foods

View full text Add to dashboard Cite

show abstract

“…synthesis, transformation into competent bacterial cells for its amplification, extraction, purification, animal immunization, assessment of immune responses, clinical trials, approval, and manufacturing (Papukashvili et al, 2022b;Rcheulishvili et al, 2022). Steps that are needed for developing a potentially universal DNA-based anti-mpox multi-epitope vaccine are given in Figure 9.…”

Section: Figurementioning

confidence: 99%

Design, evaluation, and immune simulation of potentially universal multi-epitope mpox vaccine candidate: focus on DNA vaccine

et al. 2023

Self Cite

View full text Add to dashboard Cite

Monkeypox (mpox) is a zoonotic infectious disease caused by the mpox virus. Mpox symptoms are similar to smallpox with less severity and lower mortality. As yet mpox virus is not characterized by as high transmissibility as some severe acute respiratory syndrome 2 (SARS-CoV-2) variants, still, it is spreading, especially among men who have sex with men (MSM). Thus, taking preventive measures, such as vaccination, is highly recommended. While the smallpox vaccine has demonstrated considerable efficacy against the mpox virus due to the antigenic similarities, the development of a universal anti-mpox vaccine remains a necessary pursuit. Recently, nucleic acid vaccines have garnered special attention owing to their numerous advantages compared to traditional vaccines. Importantly, DNA vaccines have certain advantages over mRNA vaccines. In this study, a potentially universal DNA vaccine candidate against mpox based on conserved epitopes was designed and its efficacy was evaluated via an immunoinformatics approach. The vaccine candidate demonstrated potent humoral and cellular immune responses in silico, indicating the potential efficacy in vivo and the need for further research.

show abstract

“…The therapeutic uses of RNA show great promise but are still in the developmental stages (Dolgin, 2021;Sahin et al, 2014). Included in these is the use of mRNA for vaccines (Rcheulishvili et al, 2022). Initially, the use of mRNA vaccines was explored in animal models including the mouse and agricultural animals such as pigs and cows (Geall et al, 2012;Lutz et al, 2017;Schnee et al, 2016).…”

Section: Vaccinementioning

confidence: 99%

Forensic analysis of the 38 subject deaths in the 6-Month Interim Report of the Pfizer/BioNTech BNT162b2 mRNA Vaccine Clinical Trial

Michels,

Perrier,

Kunadhasan

et al. 2023

Vaccine Theory Prac & Res

View full text Add to dashboard Cite

The analysis reported here is unique in that it is the first study of the original data from the Pfizer/BioNTech BNT162b2 mRNA vaccine clinical trial (CA4591001) to be carried out by a group unaffiliated with the trial sponsor. Our study is a forensic analysis of the 38 trial subjects who died between July 27, 2020, the start of Phase 2/3 of the clinical trial, and March 13, 2021, the data end date of their 6-Month Interim Report. Phase 2/3 of the trial involved 44,060 subjects who were equally distributed into two groups and received Dose 1 of either the BNT162b2 mRNA vaccinated or the Placebo control (0.9% normal saline). At Week 20, when the BNT162b2 mRNA vaccine received Emergency Use Authorization from the U.S. FDA, subjects in the placebo arm were given the option to be BNT162b2 vaccinated. All but a few accepted. Surprisingly, a comparison of the number of subject deaths per week during the 33 Weeks of this study found no significant difference between the number of deaths in the vaccinated versus placebo arms for the first 20 weeks of the trial, the placebo-controlled portion of the trial. After Week 20, as subjects in the Placebo were unblinded and vaccinated, deaths among this still unvaccinated cohort of this group slowed and eventually plateaued. Deaths in the BNT162b2 vaccinated subjects continued at the same rate. Our analysis revealed inconsistencies between the subject data listed in the 6-Month Interim Report and publications authored by Pfizer/BioNTech trial site administrators. Most importantly, we found evidence of an over 3.7-fold increase in number of deaths due to cardiovascular events in BNT162b2 vaccinated subjects compared to Placebo controls. This significant adverse event signal was not reported by Pfizer/BioNTech. Potential sources of these data inconsistencies are identified.

show abstract

Promising strategy for developing mRNA-based universal influenza virus vaccine for human population, poultry, and pigs– focus on the bigger picture

Cited by 7 publications

References 97 publications

The Public Health Importance and Management of Infectious Poultry Diseases in Smallholder Systems in Africa

The Public Health Importance and Management of Infectious Poultry Diseases in Smallholder Systems in Africa

Design, evaluation, and immune simulation of potentially universal multi-epitope mpox vaccine candidate: focus on DNA vaccine

Forensic analysis of the 38 subject deaths in the 6-Month Interim Report of the Pfizer/BioNTech BNT162b2 mRNA Vaccine Clinical Trial

Contact Info

Product

Resources

About